Botensilimab (anti-CTLA4) and balstilimab (anti-PD-1) have been studied in a phase Ia/b trial that included previously treated MSS CRC patients, with an ORR of 22%, a DCR of 73%, and the median duration of response not reached. The gene discussed is PDCD1; the disease is colorectal carcinoma.